Esperion
Esperion Therapeutics has named Mark E. McGovern as a Director.
Esperion is a clinical-stage biotech developing oral, low-density lipoprotein cholesterol (LDL-C)-lowering therapies for the treatment of hypercholesterolemia.
McGovern was previously responsible for the clinical development of Pravachol (pravastatin) during his eleven-year career at Bristol-Myers Squibb. Later, he oversaw trials for Niaspan, Advicor and Simcor at Kos Pharmaceuticals.